Genmab A-S

Yahoo Finance • 2 months ago

Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics

We recently published a list of 12 Most Profitable Growth Stocks To Invest In. In this article, we are going to take a look at where Genmab (NASDAQ:GMAB) stands against other most profitable growth stocks to invest in. After the September... Full story

Yahoo Finance • 3 months ago

Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?

We recently published a list of the 7 Best Revenue Growth Stocks to Buy According to Analysts. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other best revenue growth stocks to buy accord... Full story

Yahoo Finance • 3 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab A/S Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The increase is effected without... Full story

Yahoo Finance • 4 months ago

Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers

We recently compiled a list of the 10 Best Affordable Stocks Under $40 According to Short Sellers.In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other affordable stocks under $40. Several... Full story

Yahoo Finance • 5 months ago

BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products

BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products Monday, BioNTech SE (NASDAQ:BNTX) reported deeper losses in the second quarter of 2024, with an EPS loss of... Full story

Yahoo Finance • 6 months ago

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Genmab A/S Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcorita... Full story

Yahoo Finance • 7 months ago

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Genmab A/S Media Release COPENHAGEN, Denmark; June 2, 2024 Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with r... Full story

Yahoo Finance • 7 months ago

Genmab Completes Acquisition of ProfoundBio

Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-d... Full story

Yahoo Finance • 8 months ago

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this patient population to have positive... Full story

Yahoo Finance • 8 months ago

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer

TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer Conversion to full approval from accelerated approval is based on positiv... Full story

Yahoo Finance • 9 months ago

30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the eve... Full story

Yahoo Finance • 10 months ago

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S Media Release COPENHAGEN, Denmark; February 27, 2024 FDA grants Priority Review with target action date of June 28, 2024 Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating clinically meaningful trea... Full story

Yahoo Finance • 10 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Genmab A/S Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses th... Full story

Yahoo Finance • 10 months ago

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Genmab A/S Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and employees of the company as wel... Full story

Yahoo Finance • 10 months ago

Genmab: Growth Is Still a Better Choice

Genmab AS (NASDAQ:GMAB) is one of the largest Danish pharmaceutical companies focused on developing medicines to treat patients with cancer, multiple sclerosis, thyroid eye disease and various autoimmune diseases. Investment thesis Genma... Full story

Yahoo Finance • 11 months ago

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

Validation is supported by data from Phase 3 innovaTV 301 trial COPENHAGEN, Denmark, February 02, 2024--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has va... Full story

Yahoo Finance • 12 months ago

12 High Growth International Stocks to Buy

In this article, we discuss the 12 high growth international stocks to buy. If you want to read about some more high growth international stocks, go directly to 5 High Growth International Stocks to Buy. There is general optimism on Wall... Full story

Yahoo Finance • last year

Genmab to Hold 2023 R&D Update and ASH Data Review Meeting

Genmab A/S Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 12, 2023 – Genmab A/S (Nasdaq: GMAB) will hold its 2023 R&D Update and ASH Data Review Meeting today, Dece... Full story

Yahoo Finance • last year

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follic... Full story

Yahoo Finance • last year

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

-  Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th American Society of Hematology (ASH) congres... Full story